SP-146 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM. SP-146 can be used for the research of triple negative breast cancer (TNBC).
|Solubility (25°C)||DMSO 91 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Kay Geert A Hermann, et al. RMD Open. What amount of structural damage defines sacroiliitis: a CT study
 Naga Rajiv Lakkaniga, et al. Eur J Med Chem. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
 David Jung, et al. J Cyst Fibros. Circulating CRP and calprotectin to diagnose CF pulmonary exacerbations
 K Schlegel, et al. Z Naturforsch C J Biosci. The pyoverdins of Pseudomonas sp. 96-312 and 96-318
 S Gupta, et al. J Commun Dis. Serodiagnosis of tuberculosis
|Related Aurora Kinase Products|
WAY-661516 is a Aurora kinase A inhibitor.
WAY-638641 is a Aurora kinase A inhibitor.
WAY-636982 is a Aurora kinase A inhibitor.
WAY-636900 is a Aurora kinase A inhibitor.
WAY-635767 is a Aurora kinase A inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.